AVAH Aveanna Healthcare Holdings Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
AVAH Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Care Facilities
Current Price
Live
$8.68
Analyst Target
$11.0
+26.7%
Upside
52W High
$10.32
52W Low
$3.67
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.81B
P/E
23.46
ROE
N/A
Profit margin
3.3%
Debt/Equity
152.32
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
AVAH exhibits a Piotroski F-Score of 5/9, indicating stable financial health, but lacks an Altman Z-Score, limiting bankruptcy risk assessment. The stock trades above its Graham Number of $0.63 and intrinsic value of $2.59, reflecting high growth expectations, supported by strong revenue growth of 22.2% and robust analyst target of $11.00. However, extreme valuation multiples like a Price/Book of 184.68 and insider selling worth $295.49M over 6 months raise sustainability concerns. While recent earnings surprises have been exceptionally strong, declining Q/Q EPS and high leverage (Debt/Equity: 152.32) present material risks.
Key Strengths
Strong revenue growth (22.2% YoY) outpaces sector average of 62.62% in context of profitability
High operating margin (11.00%) and gross margin (33.57%) indicate pricing power and cost control
Impressive earnings surprise history with 3 out of last 4 quarters beating estimates, averaging +362.87%
Analyst consensus supports upside with $11.00 target price implying ~27% potential return
Improving profitability trend from negative to positive EPS since 2023
Key Risks
Extremely high Debt/Equity ratio of 152.32 signals severe financial leverage and refinancing risk
Insider selling activity (11 transactions, $295.49M) suggests lack of confidence from executives
Price/Book of 184.68 is exceptionally high, indicating possible overvaluation relative to book equity
Piotroski F-Score of 5 is stable but not strong, with no Altman Z-Score to confirm distress risk
Most recent Q/Q EPS growth declined by 16.7%, indicating potential near-term earnings weakness
AI Fair Value Estimate
Based on comprehensive analysis
$6.5
-25.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
45
70
60
52
0
AI Verdict
Cautiously optimistic with significant valuation and leverage risks
Key drivers: High revenue growth and earnings momentum, Rich valuation multiples, Aggressive insider selling, Strong operating margins, Extreme capital structure leverage
Confidence
70%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 13.97 is below current P/E of 23.46, suggesting earnings recovery priced in
- Price/Sales of 0.79 is below sector average implied by high P/E peers
Watchpoints
- Current P/E of 23.46 is high for a company with inconsistent earnings history
- Price/Book of 184.68 is extremely elevated, indicating severe overvaluation relative to equity
- Stock trades at 13.7x intrinsic value (Graham: $0.63) and 3.3x growth-based intrinsic ($2.59)
Future
70/100
Ref Growth rates
Positives
- Revenue growth of 22.2% YoY is strong and sustainable in healthcare services
- Analyst target of $11.00 implies confidence in future earnings trajectory
- Forward P/E of 13.97 suggests improving earnings outlook
Watchpoints
- Q/Q EPS growth declined by 16.7%, signaling near-term headwinds
- No PEG ratio due to inconsistent earnings, limiting growth-adjusted valuation
Past
60/100
Ref Historical trends
Positives
- Transitioned from consistent losses to profitability in recent quarters
- Long-term 3Y return of +583.5% shows strong price momentum
Watchpoints
- 5Y price change of -27.7% indicates long-term underperformance
- Earnings history includes multiple negative quarters and large misses
Health
52/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 5/9 indicates stable financial condition
- Current ratio (1.23) and quick ratio (1.15) suggest short-term liquidity adequacy
Watchpoints
- Debt/Equity of 152.32 is dangerously high, indicating extreme financial risk
- No Altman Z-Score available to assess bankruptcy risk
- ROE and ROIC missing, limiting return efficiency analysis
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout history
- Dividend strength score of 0/100 confirms absence of income appeal
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.68
Analyst Target
$11.0
Upside/Downside
+26.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AVAH and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AVAH
Aveanna Healthcare Holdings Inc.
Primary
|
-27.7% | +583.5% | +75.7% | +119.2% | -0.3% | -5.9% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
23.46
Forward P/E
13.97
PEG Ratio
N/A
P/B Ratio
184.68
P/S Ratio
0.79
EV/Revenue
1.38
EV/EBITDA
11.9
Market Cap
$1.81B
Profitability
Profit margins and return metrics
Profit Margin
3.29%
Operating Margin
11.0%
Gross Margin
33.57%
ROE
N/A
ROA
9.31%
Growth
Revenue and earnings growth rates
Revenue Growth
+22.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
152.32
High debt
Current Ratio
1.23
Good
Quick Ratio
1.15
Good
Cash/Share
$0.73
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-12
$N/A
2025-11-06
$0.15
+14.9% surprise
2025-08-07
$0.18
+405.5% surprise
2025-05-08
$0.03
+668.2% surprise
Healthcare Sector Comparison
Comparing AVAH against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
23.46
This Stock
vs
164.56
Sector Avg
-85.7%
(Discount)
Profit Margin
3.29%
This Stock
vs
-20.78%
Sector Avg
-115.9%
(Weaker)
Debt to Equity
152.32
This Stock
vs
6.16
Sector Avg
+2371.6%
(Higher)
Revenue Growth
22.2%
This Stock
vs
137.39%
Sector Avg
-83.8%
(Slower)
Current Ratio
1.23
This Stock
vs
3.36
Sector Avg
-63.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AVAH
Aveanna Healthcare Holdings Inc.
|
NEUTRAL | $1.81B | 23.46 | -% | 3.3% | $8.68 | |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | SHANER JEFFREY | Chief Executive Officer | Sale | 84,960 | $689,985 |
| 2026-01-02 | REISZ EDWIN C | Officer | Sale | 50,970 | $413,942 |
| 2026-01-02 | CUNNINGHAM PATRICK A | Officer | Sale | 36,015 | $292,488 |
| 2026-01-02 | STEWART DEBORAH | Officer | Sale | 34,616 | $281,126 |
| 2026-01-02 | BUCKHALTER MATTHEW | Chief Financial Officer | Sale | 53,077 | $431,054 |
| 2025-10-24 | VIGANO PAUL R | Beneficial Owner of more than 10% of a Class of Security | Sale | 1,500,000 | $13,500,000 |
| 2025-10-24 | WILLIAMS ROBERT M JR | Beneficial Owner of more than 10% of a Class of Security | Sale | 1,500,000 | $13,500,000 |
| 2025-10-24 | J.H. WHITNEY EQUITY PARTNERS VII, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | 1,251,909 | $11,267,181 |
| 2025-10-21 | VIGANO PAUL R | Beneficial Owner of more than 10% of a Class of Security | Sale | 10,000,000 | $90,000,000 |
| 2025-10-21 | WILLIAMS ROBERT M JR | Beneficial Owner of more than 10% of a Class of Security | Sale | 10,000,000 | $90,000,000 |
| 2025-10-21 | J.H. WHITNEY EQUITY PARTNERS VII, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | 8,346,059 | $75,114,531 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
10 analysts
Barclays
2026-01-16
Overweight
Overweight
UBS
2026-01-15
Neutral
Neutral
RBC Capital
2026-01-15
Sector Perform
Sector Perform
William Blair
2025-12-08
Outperform
BMO Capital
2025-11-13
Outperform
UBS
2025-11-07
Neutral
Neutral
Truist Securities
2025-11-07
Hold
Hold
Jefferies
2025-10-28
Buy
Buy
RBC Capital
2025-10-24
Sector Perform
Sector Perform
UBS
2025-10-13
Neutral
Neutral
Past News Coverage
Recent headlines mentioning AVAH from our newsroom.
Newest → oldest
No matching news yet.